Proheme Diagnostics

ProHeme is a newly established spin-off company from Macquarie University, dedicated to identifying blood and body fluid biomarkers for various neurodegenerative disorders, focusing primarily on Multiple Sclerosis (MS). Our multidisciplinary team operates at the intersection of scientific innovation and medical expertise, unified by a shared purpose: to revolutionise MS diagnosis and prognosis.

Breakthrough Invention

Introducing the world's first blood test for Multiple Sclerosis, our pioneering research addresses the significant diagnostic challenges of MS. The first test enables early detection, crucial for timely intervention, while the second accurately predicts disease progression, allowing for personalised treatment plans. Together, these tests aim to greatly improve diagnostic accuracy, enhance patient care, and offer renewed hope to millions affected by MS worldwide.